You are here: Home » International » News » Companies
Business Standard

AstraZeneca set for 'modest' profit from Covid-19 vaccine

The Oxford/AstraZeneca vaccine has until now been sold on a not-for-profit basis

Topics
Coronavirus Vaccine | Coronavirus | AstraZeneca

Press Trust of India  |  London 

Photo: Bloomberg
Covid-19 vaccine sales in Q4 2021 are expected to be a blend of the original pandemic agreements and new orders

AstraZeneca, the UK-headquartered biopharmaceutical company behind the manufacture of the Oxford University developed COVID-19 vaccine, said on Friday that it plans to start earning a modest profit from the doses being sold as part of new orders.

The Oxford/vaccine, which is also being manufactured by the Serum Institute of India (SII) as part of an agreement, has until now been sold on a not-for-profit basis.

The company is now expecting to progressively transition the vaccine to modest profitability as new orders are received, notes the AstraZeneca's latest financial results update.

COVID-19 vaccine sales in Q4 2021 are expected to be a blend of the original pandemic agreements and new orders, with the large majority coming from pandemic agreements, it said.

In its latest financials, the Anglo-Swedish biopharma major said it had supplied USD 2.22 billion worth of the drug, representing delivery of 580 million doses, in the first nine months of 2021.

When including partners such as SII sub-licensed to make the vaccine, it has released 1.5 billion doses for supply in more than 170 countries, the company said.

"We are proud as a company of the impact we have had we've saved millions of hospitalisations. The (AstraZeneca) team continues to do a stellar job," chief executive Pascal Soriot told the BBC.

The company had said it would only start to make money from the vaccine when COVID-19 was no longer a pandemic. It has now revealed a series of for-profit agreements for next year, which are likely to have limited profit contribution.

"The virus is becoming endemic which means we have to learn to live with it. We started this to help, but we said we would transition (to making a profit on the vaccine). It's not something we see as a huge profit-earner," said Soriot.

The company plans to have tiered pricing for countries to make sure the vaccine remains affordable for all.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, November 12 2021. 21:44 IST
RECOMMENDED FOR YOU
.